Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - A retrospective analysis: JMTO LC03-02

BMC Research Notes

Volumn 2, Issue , 2009, Pages

  Nakagawa, Masatsugu ^a,b,d   Nishimura, Tsutomu ^a,d   Teramukai, Satoshi ^a,d   Tada, Harue ^a,d   Tanaka, Fumihiro ^c,d   Yanagihara, Kazuhiro ^b,d   Furuse, Kiyoyuki ^d   Wada, Hiromi ^b,d   Fukushima, Masanori ^a,d,e  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d The Japan Multinational Trial Organization   (Japan)

^e Translational Research Informatics Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77049124105     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-2-157     Document Type: Article

References (24)

1. JM Samet, Epidemiology of Lung Cancer New York, Marcel Dekker, Inc 1994 1
2. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group, BMJ 1995 311 899 909 7580546
3. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. P Bonomi K Kim D Fairclough D Cella J Kugler E Rowinsky M Jiroutek D Johnson, J Clin Oncol 2000 18 623 631 10653877
4. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIb or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. RM Rudd NH Gower SG Spiro TG Eisen PG Harper JA Littler M Hatton PW Johnson WM Martin EM Rankin LE James WM Gregory W Qian SM Lee, J Clin Oncol 2005 23 142 153 10.1200/JCO.2005.03.037 15625369
5. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. F Fossella JR Pereira J von Pawel A Pluzanska V Gorbounova E Kaukel KV Mattson R Ramlau A Szczesna P Fidias M Millward CP Belani, J Clin Oncol 2000 18 2354 2362 10856094 (Pubitemid 30415821)
6. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. FA Shepherd J Dancey R Ramlau K Mattson R Gralla M O'Rourke N Levitan L Gressot M Vincent R Burkes S Coughlin Y Kim J Berille, J Clin Oncol 2000 18 2095 2103 10811675 (Pubitemid 30324363)
7. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Baselga D Rischin M Ranson H Calvert E Raymond DG Kieback SB Kaye L Gianni A Harris T Bjork SD Averbuch A Feyereislova H Swaisland F Rojo J Albanell, J Clin Oncol 2002 20 4292 4302 10.1200/JCO.2002.03.100 12409327 (Pubitemid 35266289)
8. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. RS Herbst AM Maddox ML Rothenberg EJ Small EH Rubin J Baselga F Rojo WK Hong H Swaisland SD Averbuch J Ochs PM LoRusso, J Clin Oncol 2002 20 3815 3825 10.1200/JCO.2002.03.038 12228201 (Pubitemid 35050835)
9. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. K Nakagawa T Tamura S Negoro S Kudoh N Yamamoto N Yamamoto K Takeda H Swaisland I Nakatani M Hirose RP Dong M Fukuoka, Ann Oncol 2003 14 922 930 10.1093/annonc/mdg250 12796031
10. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. M Fukuoka S Yano G Giaccone T Tamura K Nakagawa JY Douillard Y Nishiwaki J Vansteenkiste S Kudoh D Rischin R Eek T Horai K Noda I Takata E Smit S Averbuch A Macleod A Feyereislova RP Dong J Baselga, J Clin Oncol 2003 21 2237 2246 10.1200/JCO.2003.10.038 12748244
11. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. MG Kris RB Natale RS Herbst TJ Lynch Jr D Prager CP Belani JH Schiller K Kelly H Spiridonidis A Sandler KS Albain D Cella MK Wolf SD Averbuch JJ Ochs AC Kay, JAMA 2003 290 2149 2158 10.1001/jama.290.16.2149 14570950 (Pubitemid 37432975)
12. Severe acute interstitial pneumonia and gefitinib. A Inoue Y Saijo M Maemondo K Gomi Y Tokue Y Kimura M Ebina T Kikuchi T Moriya T Nukiwa, Lancet 2003 361 137 139 10.1016/S0140-6736(03)12190-3 12531582
13. Lessons from gefitinib-induced interstitial lung disease in Japan: Problems in approval, pharmacovigilance, and regulatory decision-making procedures. T Nishimura H Tada M Nakagawa S Teramukai S Matsui M Fukushima, Pharmacy Practice 2006 4 168 178 http://www.pharmacypractice.org/vol04/pdf/168- 178-en.pdf
14. Revisions in the international system for staging lung cancer. CF Mountain, Chest 1997 111 1710 1717 10.1378/chest.111.6.1710 9187198
15. Pharmacovigilance-related topics at the level of the International Conference on Harmonisation (ICH). P Bahri P Tsintis, Pharmacoepidemiology and Drug Safety 2005 14 377 387 10.1002/pds.1043 15517542
16. New guidelines to evaluate the response to treatment in solid tumors. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther, J Natl Cancer Inst 2000 92 205 216 10.1093/jnci/92.3.205 10655437 (Pubitemid 30099779)
17. Reporting results of cancer treatment. AB Miller B Hoogstraten M Staquet A Winkler, Cancer 1981 47 207 214 10.1002/1097-0142(19810101)47:1<207::AID- CNCR2820470134>3.0.CO;2-6 7459811
18. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. H Kaneda K Tamura T Kurata H Uejima K Nakagawa M Fukuoka, Lung Cancer 2004 46 247 54 10.1016/j.lungcan.2004.04.032 15474673
19. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. R Maruyama Y Nishiwaki T Tamura N Yamamoto M Tsuboi K Nakagawa T Shinkai S Negoro F Imamura K Eguchi K Takeda A Inoue K Tomii M Harada N Masuda H Jiang Y Itoh Y Ichinose N Saijo M Fukuoka, J Clin Oncol 2008 26 4244 4252 10.1200/JCO.2007.15.0185 18779611
20. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. T Takano Y Ohe M Kusumoto U Tateishi S Yamamoto H Nokihara N Yamamoto I Sekine H Kunitoh T Tamura T Kodama N Saijo, Lung Cancer 2004 45 93 104 10.1016/j.lungcan.2004.01.010 15196739
21. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. K Hotta K Kiura M Tabata S Harita K Gemba T Yonei A Bessho T Maeda T Moritaka T Shibayama K Matsuo K Kato A Kanehiro Y Tanimoto K Matsuo H Ueoka M Tanimoto, Cancer J 2005 11 417 424 10.1097/00130404-200509000-00010 16259873 (Pubitemid 41725734)
22. The results of Gefitinib Prospective Investigation. S Yoshida, Medicine and Drug Journal 2005 41 772 789
23. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. M Ando I Okamoto N Yamamoto K Takeda K Tamura T Seto Y Ariyoshi M Fukuoka, J Clin Oncol 2006 24 2549 2556 10.1200/JCO.2005.04.9866 16735708
24. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. S Kudoh H Kato Y Nishiwaki M Fukuoka K Nakata Y Ichinose M Tsuboi S Yokota K Nakagawa M Suga Japan Thoracic Radiology Group H Jiang Y Itoh A Armour C Watkins T Higenbottam F Nyberg, Am J Respir Crit Care Med 2008 177 1348 1357 10.1164/rccm.200710-1501OC 18337594